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Abstract
Background: Goatpox is an economically important disease in goat and sheep-producing areas of the world.
Many vaccine strategies developed to control the disease are not yet completely successful. Hairpin expression
vectors have been used to induce gene silencing in a large number of studies on viruses. However, none of these
studies has been attempted to study GTPV. In the interest of exploiting improved methods to control goat pox, it
is participated that RNAi may provide effective protection against GTPV. In this study we show the suppression of
Goatpox virus (GTPV) replication via knockdown of virion core protein using RNA interference.
Results: Four short interfering RNA (siRNA) sequences (siRNA-61, siRNA-70, siRNA-165 and siRNA-296) against a
region of GTPV ORF095 were selected. Sense and antisense siRNA-encoding sequences separated by a hairpin loop
sequence were designed as short hairpin RNA (shRNA) expression cassettes under the control of a human U6
promoter. ORF095 amplicon was generated using PCR, and then cloned into pEGFP-N1 vector, named as p095/
EGFP. p095/EGFP and each of the siRNA expression cassettes (p61, p70, p165 and p296) were co-transfected into
BHK-21 cells. Fluorescence detection, flow cytometric analysis, retro transcription PCR (RT-PCR) and real time PCR
were used to check the efficiency of RNAi. The results showed that the ORF095-specific siRNA-70 effectively down-
regulated the expression of ORF095. When Vero cells were transfected with shRNA expression vectors (p61/GFP,
p70/GFP, p165/GFP and p296/GFP) and then infected with GTPV, GTPV-ORF095-70 was found to be the most
effective inhibition site in decreasing cytopathic effect (CPE) induced by GTPV. The results presented here indicated
that DNA-based siRNA could effectively inhibit the replication of GTPV (approximately 463. 5-fold reduction of viral
titers) on Vero cells.
Conclusions: This study demonstrates that vector-based shRNA methodology can effectively inhibit GTPV
replication on Vero cells. Simultaneously, this work represents a strategy for controlling goatpox, potentially
facilitating new experimental approaches in the analysis of both viral and cellular gene functions during of GTPV
infection.
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GTPV is a member of the Genus Capripoxvirus of the
family Poxviridae [1], which also includes the Sheeppox
virus (SPPV) and the Lumpy Skin Disease Virus (LSDV)
of cattle. Both sheeppox and goatpox are endemic in
Africa, the Middle East and many countries in Asia, and
the diseases caused by these viruses have a significant
economic impact on the livestock industry in Africa and
Asia [2]. GTPV genome is approximately 150 kbp dou-
ble-stranded DNA, which composes at least 147 putative
genes, including conserved replicative and structural
genes and genes likely involved in virulence and host
range [3]. ORF095 encodes the virion protein which
constitutes a great part of the total protein content of
the virion and is essential during the assembly and dis-
assembly of virion. It is similar to myxoma virus
(MYXV) M093L (accession no.AF170726) [4,5] and vac-
cinia virus (VACV) A4L (accession no.M35027) that
encodes a 39 kDa acidic protein, a part of the viral core,
and is synthesized at late stages after infection [6,7].
RNA-mediated interference (RNAi) is a conserved
gene-silencing mechanism, where by the double-
stranded RNA matching is used as a signal to trigger
the sequence-specific degradation of homologous
mRNA [8]. RNAi can be triggered by chemically synthe-
sised and enzymatically produced 21-25 nt long RNA
duplexes in mammalian cells [9,10]. Since the effect of
short interfering RNAs (siRNAs) is generally temporal
in transfected animal cells, small RNA expression vec-
tors have been developed to induce long-lasting RNA
silencing in mammalian cells [11-14]. RNAi represents a
new antiviral method and is being increasingly used to
inhibit the replication of viral pathogens [15] such as
foot-and-mouth disease [16,17], porcine reproductive
and respiratory syndrome virus [18], Newcastle disease
virus [19], classical swine fever virus [20] and Monkey-
pox virus [21]. Hairpin expression vectors have been
used to induce gene silencing in a large number of stu-
dies on viruses [11,22-26].
This study provides not only an experimental basis for
the development of a new anti-GTPV strategy, but also
for a new approach to the study of GTPV infection and
replication.
Materials and methods
Viruses and cells
Goatpox virus strain A/Goat/Qinghai/AV40/2006(a cell-
adapted strain) was used in this study and maintained in
African green monkey kidney cells (Vero). Baby Ham-
ster Kidney cells (BHK-21) and the GTPV permissive
cell line Vero (Lanzhou Veterinary Research Institute,
C h i n )w e r ec u l t u r e di nD u l b e c c o ’s modified Eagle’s
medium (DMEM; Sigma) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Hangzhou, China),
100 U/ml penicillin and 100 μg/ml streptomycin
(Sigma). Cultures were incubated at 37°C with 5% CO2.
Construction of plasmids
The cDNA cassettes corresponding to the conserved
gene of the GTPV genome was cloned into the pEGFP-
N1 vector (Figure 1A). Directed cloning PCR was used
to amplify the ORF095 gene, using the following pri-
mers (sense: 5’-GTCCTCGAGATGGACTTCAT-
GAAAAAATATACTAA-3’ and antisense: 5’-
GCGGATCCTTGCTGTTATTATCATCTAGTTTG-3’)
used for amplification contained the target sequences
for XhoI( CTCGAG) and BamHI (GGATCC) incorpo-
rated at the 5’ of the viral complementary sequence.
Forward primer contained an ATG sequence, before the
sequence that codified for the protein, as a start initia-
tion codon of protein translation. The reverse primer
uncontained a TTA sequence, which was used in the
characterization of ORF095 protein and EGFP co-
expression. PCR products were digested with XhoIa n d
BamHI, and cloned into the pEGFP-N1 expression vec-
tor (Invitrogen, Inc., Shanghai, China). The final con-
struct p095/EGFP (Figure 1A) was analyzed by
restriction digestion and sequenced. Plasmids used for
Figure 1 Schematic representations of target construct, siRNA-
expressing plasmids, and predicted siRNAs. (A)Position of target
siRNAs: GTPV-ORF095-61, GTPV-ORF095-70, GTPV-ORF095-165 and
GTPV-ORF095-296. (B) siRNA expressing plasmids and predicted
siRNAs. An inverted repeat is inserted at the 3’-end of the human
U6 promoter. The forward sequence of the repeat is 21 or 63 nt
long, corresponding to the region of interest of the ORF095 gene.
The forward and reverse motifs are separated by a 7-nt spacer, 5’-
TCAAGAG-3’. The transcriptional termination signal of five Ts is
added at the 3’-end of the inverted repeat. The synthesized RNA is
predicted to fold back to form a hairpin dsRNA, which would be
finally processed into the putative siRNAs.
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TM Plasmid DNA Purification System (Promega, USA)
and quantified by Biophotometer (Eppendorf, Germany).
Target sequence selection and vector construction
As the AAGN18UU sequence (N, any nucleotide) has
been found to be preferred for siRNA-mediated gene
silencing under the control of the PolU6 promoter [27],
we searched for this sequence in the ORF of ORF095
gene. Four fragments (ORF095-61, ORF095-70,
ORF095-165 and ORF095-296) in the coding region of
ORF095 gene were selected according to the web-based
criteria (http://www.ambion.com). These selected
sequences were then submitted to a BLAST searching
against human genome sequence to check whether or
not these potential targets have homologues in the
human genome was not targeted. To construct hairpin
siRNA expression cassette, the following DNA oligonu-
cleotides were synthesized: GTPV-ORF095-61, GTPV-
ORF095-70, GTPV-ORF095-165 and GTPV-ORF095-
296 (Figure 1A). The 21 nt target sequences served as a
basis for the design of the two complementary 51-
53mer siRNA template oligonucleotides that were
synthesized, annealed, and inserted into BamHI and
BbsI sites of the siRNA expression vectors pGPU6/Neo
and pGPU6/GFP/Neo (GenePharma Co., Ltd, Shanghai,
China), respectively. The recombinant plasmids were
designated as p61, p61/GFP, p70, p70/GFP, p165, p165/
GFP, p296 and p296/GFP. The pC and pC/GFP negative
controls (GenePharma Co., Ltd, Shanghai, China) were
negative control plasmid, which encode hairpin siRNA
that does not have homologues in mice, human and
Carpripoxvirus genome databases.
Transfection of the siRNA expression cassettes into BHK-
21 cells
BHK-21 cells were seeded in six-well plates and cultured
at 37°C and 5% CO2 overnight. When the cells showed
70-80% confluence, 2.5 μg of p61, p70, p165 or p296
each were cotransfected with an equal amount of p095/
EGFP using FuGENE HD Transfection Reagent (Roche,
Germany) according to the Manufacturer’s recommen-
dations, respectively. Simultaneously, 2.5 μg of p095/
EGFP were cotransfected with 2.5 μgo fp C .N o n - t r a n s -
fected BHK-21 cells were also used as a control.
Analysis of EGFP expression in BHK-21 cells and flow
cytometry assay
After an additional 24 h of incubation, cells were
observed for the expression of green fluorescent protein
in the transfected cells was monitoring fluorescent
microscope (Olympus, Japan).
Cells were further subjected to fluorescence-activated
cell sorting (FACS). At 48 h posttransfection, the
transfected cells and the controls were washed gently in
phosphate-buffered saline (PBS), trypsinized and resus-
pended in PBS. EGFP positive cells and EGFP expres-
sion signal were evaluated by the FACS Calibur Flow
Cytometry System (Becton Dickinson, USA).
Reverse transcription (RT)-PCR
To confirm the efficacy of RNAi, RT-PCR was used to
amplify the target gene in the transfected cells. Total
RNA was extracted from BHK-21 culture with Trizol
reagent (TaKaRa, Dalian), and incubated for 1 h at 37°C
with Dnase RQ1 (TaKaRa, Dalian). To detect ORF095
mRNA expression in BHK-21 cells, RT-PCR was con-
ducted using 1.8 μg of RNA extracts with Superscript
one-step RT-PCR system (Gibco, BRL). Retrotranscrip-
tion b-actin as a control was also amplified using the
Primers 5’-CACCCGCGAGTACAACCTTC-3’ (sense)
and 5’-CCCATACCCACCATCACACC-3’ (antisense).
PCR was run for 30 cycles with 95°C for 30 s, 56°C for
45 s and 72°C for 45 s. To verify primer specificity, a
melting curve was analyzed, and RT-PCR products were
further cloned into pMD18-T for sequencing.
Real-time PCR analysis
In order to use full-length ORF095 gene as a quantita-
tive RT-PCR standard, Selected primer sequences
were CTGTCTACATGATTAACCCACTCGTTCTTC
(ORF095 FP primer), and GAAGTCGACTAC
CCCTCTCCCTATCAGGGTCATC (ORF095 RP pri-
mer). One additional primer was synthesized for quanti-
fication of the ORF095 in real-time PCR: 5-FAM-
CCTTGCTCGCGAATTTCTCACCGATAMRA- 3
(TaqMan probe). The target region of real time RT-PCR
was 263-389 bp of ORF095.
For quantitative analysis of the ORF095 gene, 100 ng
total RNA from p095/EGFP-transfected cells was mixed
with 1 μL ORF095 primer, heated to 65°C for 5 min
and chilled on ice for 2 min. To this primer template
mix was added 5× buffer (4 μL), 10 mmol/μLd N T P( 1
μL), RNasin (1 μL), AMV reverse transcriptase (1 μL,
Promega, USA) and ddH2Ot oat o t a lv o l u m eo f2 0μL.
The reaction mixture was incubated at 42°C for 45 min,
followed by inactivation of reverse transcriptase at 75°C
for 15 min. Real-time PCR was performed with the ABI
PRISM 7000 Sequence Detection System using 2 μL
transcriptase products as template under the conditions
of 95°C for 15 min, followed by 50 cycles of denatura-
tion at 95°C for 30 s, annealing, and extension at 60°C
for 30 s. The quantitative standard curve for determina-
tion of ORF095 copy number was created by real-time
PCR of standard plasmid p095/EGFP serial 10-fold dilu-
tions of a stock containing 10
8 copies/μL. The specificity
of the real-time PCR was confirmed by sequencing of
the product.
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Four siRNAs targeting ORF095 were designed to inhibit
GTPV ORF095 gene expression in BHK-21 cells. We
used a modified CMV promoter, a typical RNA polIII
promoter, to drive the transcription of the siRNAs. To
monitor the effects of the siRNAs, eukaryotic expression
plasmid p095/EGFP was constructed, in which the
ORF095 gene were fused to the 5’-end of the EGFP cod-
ing sequence, and cotransfected with their specific
siRNA expression plasmids. Sot h ei n h i b i t o r ye f f e c t so f
the ORF095-specific siRNAs on the ORF095 expression
could be indirectly evaluated by the expression of EGFP
in the transfected cells.
To test whether the expressed siRNAs inhibited GTPV
production, we first assessed the growing capacity of
GTPV in Vero cells expressing siRNAs. Vero cells were
seeded in six-well plates and cultured at 37°C and 5%
CO2 overnight. When the cell reached 70-80% conflu-
ence, 2.5 μg of p61/GFP, p70/GFP, p165/GFP or p296/
GFP each were cotransfected with an equal amount of
pC/GFP as described above, respectively. The nonspeci-
fic vector pC/GFP and non-transfected Vero cells were
also used as a control. 24 h posttransfection, the cells
were infected with GTPV at a multiplicity of infection
(moi) of about 0.01. Briefly, after removing the culture
medium, GTPV (200 μl) in infection medium (2.5 μg/ml
trypsin), respectively, were added to each well. The cul-
tures were then incubated at 37°C, 5% CO2 for 4 h, at
which point the culture medium was replaced with fresh
DMEM containing 2% fetal bovine serum.
Virus titration
To determine transfection efficiency, we monitored GFP
fluorescence intensity of transfected cells using fluores-
cent microscope analysis. Culture supernatants were col-
lected for virus titration. Six days post infection,
supernatants was harvested from the infected cultures
and virus titer (TCID50) was determined three times on
Vero cells.
Virus infectivity was determined by serial dilutions of
the samples in 96-well plates and the virus titer was cal-
culated as a TCID50 by the Reed-Muench method [28].
A viral suspension titrated at 10
-1 to 10
-8 TCID50 per
0.1 ml was used for viral challenge. Vero cells (about
80% confluent) grown in 96-well plates were transiently
transfected with 0.1 μg p61/GFP, p70/GFP, p165/GFP
and p296/GFP, respectively, per well. After 6 h of trans-
fected, the transfection medium was removed and the
cells were washed twice with DMEM medium. The
transfected cells were then infected with 100 TCID50 of
virus per 0.1 ml per well. After additional 1 h incuba-
tion, the inoculum was removed and the cells were
washed twice with DMEM medium. The cells were then
maintained in DMEM medium supplemented with 10%
fetal bovine serum for 6 days. For detecting the thera-
peutic potential of siRNA, in another parallel experi-
ment, transfection was performed 1 h post-infection
with the virus. GTPV replication in Vero cells was eval-
uated by virus titer (TCID50).
Results
Transient cellular transfection and analysis of the
targeted gene and EGFP expression in BHK-21 cells
Different siRNAs suppressed the expression of fusion
green fluorescent protein in BHK-21 cells is different.
The siRNAs targeting to the conserved region of GTPV
genome were generated in vitro by human recombinant
Dicer enzyme, as described in Figure 1B. To identify an
effective inhibitory effect of siRNAs, the cDNA cassettes
of these regions were inserted into the 5’ end of
enhanced green fluorescent protein (EGFP) gene to con-
struct reporter plasmids (Figure 2). The reporter plas-
mids were used to cotransfect BHK-21 cells with either
the homologous siRNAs or the heterologous siRNAs.
The results showed that the number of EGFP-expressing
cell was markedly reduced in the sample transfected
with homologous siRNAs than sample transfected with
heterologous siRNAs or non-transfected (Figure 3A).
FACS demonstrated that the levels of inhibition
mediated by the siRNAs were similar among the differ-
ent experiment groups and significantly higher than the
control group (cotransfection with heterologous siRNAs
or without siRNAs).
The inhibitory effects of the siRNAs on expression of
EGFP were quantitatively validated by flow cytometry 48
h posttransfection. The extent of EGFP down regulation
was assessed by the mean fluorescence of the positive
cells (LR-values) and the rate of EGFP positive cells
Figure 2 Amplification of ORF095 gene from the GTPV
genome by PCR and identification of recombinant plasmid
p095/EGFP by restriction and PCR.M 1 DNA marker DL 2000; 1&2
PCR products; M2 DNA marker 500-12000; 3 map of restriction by
BamHI and XhoI; 4 PCR product; N negative control.
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EGFP positive cells were reduced in the cells transfected
with ORF095 siRNA-specific expression plasmids p61,
p70, p165 and p296, and were reduced by 90.9%, 96.7%,
66.0%and 69.32%, respectively.
To further demonstrate the levels of inhibition, cells
were collected 48 h post-transfection and RT-PCR ana-
lysis was performed. The level of target RNA, as deter-
mined by RT-PCR, was also significantly reduced in
cells transfected with homologous siRNAs (Figure 4A).
To measure the level of gene suppression accurately,
QPCR primers and Taqman probes directing to ORF095
were designed. We also designed probes and primers
directed tob-actin sequence (serve as internal reference).
When normalized for loading differences using the b-
actin mRNA, the ORF095 message in the cells trans-
fected with p61, p70, p165 and p296 were reduced by
69%, 97%, 22%and 57% (ORF095 message copies ratios
of cells transfected with shRNA expression vectors/cells
transfected with empty vector)(Figure 4B). There was no
significant inhibition in cells transfected with the empty
vector pEGFP-N1 and nonspecific shRNA expression
vector pC. mRNA levels of ORF095 (average ORF095
mRNA levels in cells treated with p61, p70, p165, p296,
pC and empty vector were 0.416, 0.036, 1.046, 0.580,
1.345, respectively) or b-actin suggested that the
Figure 3 Transient expression of siRNAs conferred the sequence-specific inhibition of expression of GTPV ORF95 in BKH-21 cells.( A )
Fluorescence detection of cotransfection of p095/EGFP with their corresponding siRNA expression plasmids 24 h posttransfection. (B) Flow
cytometric analysis of cotransfection of p095/EGFP with their corresponding siRNA expression plasmids 48 h posttransfection. EGFP expression
level in cells cotransfected with (a) pEGFP-N1 vector; (b) p095/EGFP; (c) p095/EGFP and p61; (d) p095/EGFP and p70; (e) p095/EGFP and p165; (f)
p095/EGFP and p296; (g) p095/EGFP and pControl; (h) BHK-21 cell control. LR-Value means the rate of EGFP positive cells.
Zhao et al. Virology Journal 2012, 9:48
http://www.virologyj.com/content/9/1/48
Page 5 of 9reductions in ORF095 message did not result from poor
transfection, nonspecific inhibition or toxicity, because
the average mRNA levels of b-actin for experimental
cells were not significantly reduced compared to the
control cells. In addition, the suppressive effect was
found to be gene-specific, because the inhibitory effect
of empty vector and nonspecific shRNA expression vec-
tor pC were negligible. These results suggest that the
siRNA generated by in vitro transcription effectively and
specifically inhibit the expression of GTPV ORF095 con-
served regions in BHK-21 cells.
Interference of GTPV replication by shRNA expression
vector
To investigate whether or not knockout of ORF095
relieves cytopathic effect (CPE) induced by GTPV,
Vero cells were transfected by plasmids expressing
ORF095 protein-targeted shRNAs (p61/GFP, p70/GFP,
p165/GFP and p296/GFP), respectively. Nonspecific
shRNA expression vector pC/GFP was transfected in
parallel. 4 h post-transfection, the cultures were
infected with GTPV and checked daily. Six days later,
w ef o u n dt h a tc e l l sp r e - t r a n s f e c t e dw i t hp 7 0 / G F P
exhibited less CPE, whereas other shRNA-treated cells
and the empty vector control demonstrated the same
typical GTPV-induced CPE as cells infected only with
virus, as shown in Figure 5.
The TCID50 assay was performed to examine the
effect of siRNA on production of viable virus, and the
results (Figure 6) showed that in control cells the titers
reached 10
-5.12 TCID50/0.1 mL at 6 days post-infection.
In contrast, the titers in the cells transfected with p61/
GFP, p70/GFP, p165/GFP or p296/GFP, were 10
-3.75,
10
-2.48,1 0
-4.73 and 10
-4.66/0.1 mL 6 days post-infection
Figure 4 Analysis effect of RNAi on ORF095 by RT-PCR. (A) Cells were harvested, and transcripts were analyzed by RT-PCR amplification. The
28S, 18S, and 5.8S rRNAs were visualized under UV light for equal loading control. (B) Specific siRNA inhibits the accumulation of ORF095
message. BHK-21 cells were transfected with pEGFP-N1 and then transfected with variant shRNA-expressing vectors. Forty hours post-
transfection, total RNA was extracted and subjected to fluorescence quantitative PCR analysis. pC transfected cells and mock-transfected cells
were used as controls. The mRNA of beta actin served as an internal reference.
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2.9- fold reductions in viable virus production.
Dose-dependent inhibitory effect of shRNA expression
vector p70/GFP
To characterize the antiviral properties of most potent
siRNA construct, namely p70/GFP, Vero cells were
transfected with dilution of each construct to cover a
range of 0.1-5.0 μg in six concentrations. Overnight
transfected cells were infected with GTPV at an MOI of
0.01 and viral replication was examined at 48 h PI
(Figure 7). p70/GFP showed average viral replication
inhibition of 5.3% at the lowest tested concentration of
0.1 μg, and complete inhibition at concentrations of 2.5
μg and higher.
Discussion
RNAi is a process of sequence-specific, post-transcrip-
tional gene silencing that is initiated by double stranded
RNA. Introduction of siRNA results in degradation of
siRNA specific transcripts thus reducing the expression
of their protein product. In plants, it is a natural anti-
viral defense mechanism [29]. In mammalian cells, how-
ever, dsRNAs longer than 30 nt activate an antiviral
defense leading to the nonspecific degradation of RNA
transcripts and a general shutdown of host-cell protein
translation [30]. The successful use of siRNA in animal
cells encouraged the development of siRNA expression
vector [31] and numerous studies have demonstrated
that DNA-based siRNA is a promising approach for
antiviral therapy in mammals. RNAi represents a new
antiviral method and is being increasingly used to inhi-
bit the replication of viral pathogens [15], such as HIV-
1 [32], hepatitis C [33], influenza [34], severe acute
respiratory syndrome [35]and hepatitis E viruses [36].
This study has demonstrated the use of pGPU6/Neo or
pGPU6/GFP/Neo vector-based RNAi against GTPV, a
major pathogen of goats and sheep. Four different
siRNA targeting viral gene ORF095, one key gene
involved in GTPV replication, successfully reduced viral
replication.
The results showed that the ORF095-specific siRNAs
p70 could effectively down-regulate the expression of
Figure 5 Cytopathic effect (CPE) analysis of GTPV on Vero cells
transfected with shRNA-expressing vectors (2.5 μg each). (A):
Cells just were infected GTPV; (B)-(G):p61/GFP, p70/GFP, p165/GFP,
p296/GFP, pC/GFP and untreated cells, respectively. Except(G), all
cells were infected with GTPV(A/Goat/Qinghai/SV40/2006) isolate at
a multiplicity of infection (MOI) of 0.01. Pictures were taken at 6
days post-infection with an Olympus digital camera (Olympus,
Japan) at a magnification of × 40 with an exposure time of 1/8 s.
Figure 6 GTPV-ORF095 gene RNA-specific siRNAs can inhibit
the production of progeny virus. Vero cells transiently transfected
with empty vector or plasmid carry siRNA-61, 70, 165 or 296 were
infected with GTPV at an MOI of 0.01. Viruses were harvested and
titers were determined as described above. Mock-infected cells were
used as a control. The values given are average of three
independent experiments. Error bars indicate standard deviations.
Figure 7 Dose-dependent inhibitory effect of shRNA
expression vector p70/GFP. Vero cells were transfected with
variant p70/GFP and then infected with GTPV at an MOI of 0.01. 48
h post-infection, total RNA was extracted and subjected to
quantitative PCR analysis. Mock-transfected cells were used as
controls. The mRNA of beta actin served as an internal reference.
Black bars indicate normalized shRNA+ (cells transfected with p70/
GFP at six different concentrations ranging from 0.1 to 5.0 μg) GTPV
message copies ratios. The data shown represent average from
three experiments with the standard deviations indicated by error
bars.
Zhao et al. Virology Journal 2012, 9:48
http://www.virologyj.com/content/9/1/48
Page 7 of 9ORF095, while p61, p165 and p296 displayed weak
activity. Additionally, expression of the housekeeping
gene b-actin was also analyzed by RT-PCR and quanti-
tative real-time PCR, and no significant difference in the
expression of b-actin was observed between the siRNAs
treatment groups and pC treatment groups.
Different siRNA sequences display widely different effi-
cacies with regard to suppression of gene expression,
requiring screening of multiple sequences [37]. In this
research, we have selected four target sequences for RNA
interference by the software applications, “siRNA Target
Finder and Design Tool” available at http://www.ambion.
com/. As the ORF095 gene is well conserved in GTPV
and ORF095 protein is a virion core protein and assembly
protein in GTPV, we selected ORF095 as a target gene. In
order to generate shRNA expression cassettes quickly and
accurately, we employed a PCR-based strategy to clone
siRNA sequences. In this strategy, siRNA sequences were
designed as a single primer sequence of which 19 bp com-
plementary to the human U6 promoter were added. The
resulting PCR products are shRNA expression cassettes
including the human U6 promoter. shRNAs that have
been generated from this expression system are efficiently
processed by dicer into siRNAs. In addition, in this study,
we selected pEGFP-N1 vector that contains an EGFP gene
as report gene and can be transfected into mammalian
cells using any standard transfection method.
Vero cells transfected with p61/GFP, p70/GFP, p165/
GFP, p296/GFP and pC/GFP were examined for CPE by
virus titration. All results demonstrated that siRNA-70
is the most effective one, and result showed that mini-
mum concentration of the construct p70/GFP is 2.5 μg
required to induce maximum inhibition.
Blasting ORF095 sequence in GenBank revealed that
there were 8 Capripoxvirus isolates containing identical
sequence corresponding to ORF095. In view of the
sequences of the ORF095 genes of GTPV strains from
the same genotype, they all share high homology (95-
100%). Therefore, ORF095 gene is a good target to sup-
press GTPV replication by RNAi.
Conclusion
In conclusion, this study demonstrates that vector-based
shRNA methodology can effectively inhibit GTPV replica-
tion on Vero cells. Further study will be required to deter-
mine whether such treatment protect against GTPV
infection in vivo. Still, this work represents a strategy for
controlling goatpox, potentially facilitating new experi-
mental approaches in the analysis of both viral and cellular
gene functions during of GTPV infection.
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